Clinical trials: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.
- Trial name
- NCT02272803
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608)
- Where
- 28 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Plasma Cell Myeloma
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT05392946
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide…
- Trial name
- NCT02334865
- Testing
- Incomplete Freund's Adjuvant, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Newly Diagnosed Multiple Myeloma
A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM
This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.
- Trial name
- NCT05088330
- Testing
- Daratumumab
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1 of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral ixazomib administered in combination with lenalidomide and low-dose…
- Trial name
- NCT01217957
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 16 sites in United States
- Volunteers
- 65 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Newly Diagnosed Multiple Myeloma
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients.
- Trial name
- NCT03948035
- Testing
- Elotuzumab, Carfilzomib, Lenalidomide
- Where
- 56 sites in Austria, Germany
- Volunteers
- 576 people
- Sponsor
- Wuerzburg University Hospital
Multiple Myeloma
Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma…
- Trial name
- CCD (NCT01346787)
- Testing
- CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
- Where
- 13 sites in Italy, Netherlands
- Volunteers
- 58 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
This clinical trial is a multicenter, cohort, with one arm to study the SLP to 18 months of Velcadito scheme (velcade 1.0 mg / m2 administered over two days with melphalan and prednisone) in patients with MM diagnosis again…
- Trial name
- Velcadito (NCT02773550)
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Basque Health Service
Newly Diagnosed Multiple Myeloma
Multiple Myeloma and Exercise
This study will establich the feasibility of weight lifting exercise among patients with multiple myeloma, determine if weight lifting exercise increases lean body mass among patients with multiple myeloma and obtain further…
- Trial name
- NCT01809717
- Testing
- Weight Lifting Exercises
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma
A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
This is a multicentre; single arm study in subjects with newly diagnosed multiple myeloma. The primary objectives of this study is to assess the effect of bortezomib combination therapy (PAD regimen) followed by ASCT on bone…
- Trial name
- NCT01852799
- Testing
- PAD Followed by ASCT
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Myeloma
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00024466
- Testing
- GVAX, Autologous transplant
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients
- Trial name
- NCT04287660
- Testing
- clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma
Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview: A phase III, multi-centre, randomised controlled trial to compare standard…
- Trial name
- FiTNEss (NCT03720041)
- Testing
- R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide + ixazomib maintenance
- Where
- 110 sites in United Kingdom
- Volunteers
- 740 people
- Sponsor
- University of Leeds
Multiple Myeloma
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients…
- Trial name
- CAREMM-007 (NCT07409454)
- Testing
- anti-BCMA/CD3 bispecific antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
This phase II trial compares the combination of selinexor, daratumumab and hyaluronidase-fihj (daratumumab), velcade (bortezomib), and dexamethasone (Dara-SVD) to the usual treatment of daratumumab, lenalidomide, bortezomib, and…
- Trial name
- NCT06169215
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 27 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
This protocol corresponds to an open-label national phase II, multicenter, to assess efficacy (in terms of response rate and CR) and toxicity of bendamustine, bortezomib and prednisone (BVP) in 60 patients newly diagnosed MM.
- Trial name
- NCT01376401
- Testing
- Bendamustine, Velcade, Prednisone
- Where
- 14 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple…
- Trial name
- NCT00602641
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Melphalan
- Where
- 391 sites in United States, Israel
- Volunteers
- 306 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received…
- Trial name
- NCT01029054
- Testing
- carfilzomib, lenalidomide plus dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis…
- Trial name
- ROTATE (NCT06993675)
- Testing
- Talquetamab, Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Noffar Bar
Multiple Myeloma, Cancer
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM).
- Trial name
- NCT05145400
- Testing
- Isatuximab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center